ProCE Banner Activity

New Approaches in Urothelial Carcinoma: Expert Guidance to Improve Patient Outcomes

Multimedia
Watch this CCO on-demand webcast on new approaches for managing urothelial carcinoma and how to integrate them into clinical practice to improve patient outcomes.

Released: March 31, 2021

Expiration: March 30, 2022

No longer available for credit.

Share

Faculty

Elizabeth Plimack

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Andrea Apolo

Andrea Apolo, MD

Medical Oncology
Bethesda, Maryland

Matthew Galsky

Matthew Galsky, MD

Professor of Medicine
Director of Genitourinary Medical Oncology
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Pfizer and EMD Serono

Program Director Disclosure

Program Director

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Elizabeth R. Plimack, MD, MS, has disclosed that she has received funds for research support from Astellas, Bristol-Myers Squibb, Genentech, and Merck and consulting fees from AstraZeneca, Bristol-Myers Squibb, Calithera, Genentech, Infinity Pharma, Janssen, MEI, Merck, Pfizer, and Seattle Genetics.

Faculty Disclosure

Primary Author

Andrea Apolo, MD

Medical Oncology
Bethesda, Maryland

Andrea Apolo, MD, has no relevant conflicts of interest to report.

Matthew Galsky, MD

Professor of Medicine
Director of Genitourinary Medical Oncology
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, New York

Matthew Galsky, MD, has disclosed that he has received funds for research support from Merck and consulting fees from AstraZeneca, Bristol-Myers Squibb, Merck, Pfizer, Roche/GNE, and Seattle Genetics.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Tim Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen M. Rosenthal, PhD, has no relevant conflicts of interest to report.